78 related articles for article (PubMed ID: 20847178)
1. D-18F-fluoromethyl tyrosine imaging of bone metastases in a mouse model.
Zitzmann-Kolbe S; Strube A; Frisk AL; Käkönen SM; Tsukada H; Hauff P; Berndorff D; Graham K
J Nucl Med; 2010 Oct; 51(10):1632-6. PubMed ID: 20847178
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of D-isomers of O-11C-methyl tyrosine and O-18F-fluoromethyl tyrosine as tumor-imaging agents in tumor-bearing mice: comparison with L- and D-11C-methionine.
Tsukada H; Sato K; Fukumoto D; Nishiyama S; Harada N; Kakiuchi T
J Nucl Med; 2006 Apr; 47(4):679-88. PubMed ID: 16595503
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of O-[(18)F]fluoromethyl-D-tyrosine as a radiotracer for tumor imaging with positron emission tomography.
Urakami T; Sakai K; Asai T; Fukumoto D; Tsukada H; Oku N
Nucl Med Biol; 2009 Apr; 36(3):295-303. PubMed ID: 19324275
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of D-isomers of O-18F-fluoromethyl, O-18F-fluoroethyl and O-18F-fluoropropyl tyrosine as tumour imaging agents in mice.
Tsukada H; Sato K; Fukumoto D; Kakiuchi T
Eur J Nucl Med Mol Imaging; 2006 Sep; 33(9):1017-24. PubMed ID: 16699766
[TBL] [Abstract][Full Text] [Related]
5. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases.
Chua S; Gnanasegaran G; Cook GJ
Semin Nucl Med; 2009 Nov; 39(6):416-30. PubMed ID: 19801221
[TBL] [Abstract][Full Text] [Related]
6. Biodistribution studies on L-3-[fluorine-18]fluoro-alpha-methyl tyrosine: a potential tumor-detecting agent.
Inoue T; Tomiyoshi K; Higuichi T; Ahmed K; Sarwar M; Aoyagi K; Amano S; Alyafei S; Zhang H; Endo K
J Nucl Med; 1998 Apr; 39(4):663-7. PubMed ID: 9544678
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET.
Schirrmeister H; Guhlmann A; Elsner K; Kotzerke J; Glatting G; Rentschler M; Neumaier B; Träger H; Nüssle K; Reske SN
J Nucl Med; 1999 Oct; 40(10):1623-9. PubMed ID: 10520701
[TBL] [Abstract][Full Text] [Related]
8. An experimental study on O-[18F]fluoromethyl-L-tyrosine for differentiation between tumor and inflammatory tissues.
Suzuki M; Yamaguchi K; Honda G; Iwata R; Furumoto S; Jeong MG; Fukuda H; Itoh M
Ann Nucl Med; 2005 Oct; 19(7):589-95. PubMed ID: 16363624
[TBL] [Abstract][Full Text] [Related]
9. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
Ak I; Sivrikoz MC; Entok E; Vardareli E
Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
[TBL] [Abstract][Full Text] [Related]
10. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
[TBL] [Abstract][Full Text] [Related]
11. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management.
Hetzel M; Arslandemir C; König HH; Buck AK; Nüssle K; Glatting G; Gabelmann A; Hetzel J; Hombach V; Schirrmeister H
J Bone Miner Res; 2003 Dec; 18(12):2206-14. PubMed ID: 14672356
[TBL] [Abstract][Full Text] [Related]
12. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Flusser G; Zuriel L; Kollender Y; Lerman H; Lievshitz G; Ron I; Mishani E
J Nucl Med; 2004 Feb; 45(2):272-8. PubMed ID: 14960647
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG.
Nakamoto Y; Osman M; Wahl RL
Clin Nucl Med; 2003 Apr; 28(4):302-7. PubMed ID: 12642709
[TBL] [Abstract][Full Text] [Related]
14. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer.
Yang SN; Liang JA; Lin FJ; Kao CH; Lin CC; Lee CC
J Cancer Res Clin Oncol; 2002 Jun; 128(6):325-8. PubMed ID: 12073051
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer.
Ito S; Kato K; Ikeda M; Iwano S; Makino N; Tadokoro M; Abe S; Nakano S; Nishino M; Ishigaki T; Naganawa S
J Nucl Med; 2007 Jun; 48(6):889-95. PubMed ID: 17504877
[TBL] [Abstract][Full Text] [Related]
16. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.
Cheran SK; Herndon JE; Patz EF
Lung Cancer; 2004 Jun; 44(3):317-25. PubMed ID: 15140545
[TBL] [Abstract][Full Text] [Related]
17. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
18. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma.
Lind P; Gallowitsch HJ; Langsteger W; Kresnik E; Mikosch P; Gomez I
J Nucl Med; 1997 Mar; 38(3):348-52. PubMed ID: 9074515
[TBL] [Abstract][Full Text] [Related]
19. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET.
Daldrup-Link HE; Franzius C; Link TM; Laukamp D; Sciuk J; Jürgens H; Schober O; Rummeny EJ
AJR Am J Roentgenol; 2001 Jul; 177(1):229-36. PubMed ID: 11418435
[TBL] [Abstract][Full Text] [Related]
20. Comparison between whole-body positron emission tomography and bone scintigraphy in evaluating bony metastases of esophageal carcinomas.
Kato H; Miyazaki T; Nakajima M; Takita J; Kimura H; Faried A; Sohda M; Fukai Y; Masuda N; Fukuchi M; Manda R; Ojima H; Tsukada K; Kuwano H; Oriuchi N; Endo K
Anticancer Res; 2005; 25(6C):4439-44. PubMed ID: 16334123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
